| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000014809 |
| Receipt No. | R000017218 |
| Official scientific title of the study | Immune improvement by antiretroviral therapy in HIV-1 infected children |
| Date of disclosure of the study information | 2014/08/25 |
| Last modified on | 2017/08/11 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Immune improvement by antiretroviral therapy in HIV-1 infected children | |
| Title of the study (Brief title) | Immune improvement by ART in HIV-infected children | |
| Region |
|
|
| Condition | |||
| Condition | Human immunodeficiency virus type 1 (HIV-1) infection | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | YES | ||
| Objectives | |
| Narrative objectives1 | (1) To find appropriate immunological markers for monitoring anti-retroviral therapy (ART) effects and prognosis of HIV/AIDS (acquired immune deficiency syndrome).
(2) To figure out the genetic factors (single nucleotide polymorphisms, SNPs) related to the therapeutic outcomes and/or the side effects of ART. |
| Basic objectives2 | Others |
| Basic objectives -Others | Immunology |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Activation and differentiation of CD4+ and CD8+ cells and the proportion of different CD4+ cell subsets such as Th1/Th2/Th17/Treg (regulatory T cells), proportion of MAIT cells |
| Key secondary outcomes | (1) HIV-1 viral load (VL)
(2) CD4+ cell count (3) SNPs related to therapeutic outcomes of ART (4) Concentration of sCD14 |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) HIV(+) ART(-): children who will start ART for the first time in their life.
(2) HIV(-): HIV-negative children whose age and gender matched with subject (1) |
|||
| Key exclusion criteria | The children whose consent is not obtained | |||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroshi ICHIMURA |
| Organization | Graduate school of Medicine, Kanazawa University |
| Division name | Department of Viral infection and International Health |
| Address | 13-1, Takara-machi, Kanazawa-shi, Ishikawa, 920-8640, Japan |
| TEL | +81-76-265-2229 |
| ichimura@med.kanazawa-u.ac.jp | |
| Public contact | |
| Name of contact person | Xiuqiong Bi |
| Organization | Graduate school of Medicine, Kanazawa University |
| Division name | Department of Viral infection and International Health |
| Address | 13-1, Takara-machi, Kanazawa-shi, Ishikawa, 920-8640, Japan |
| TEL | +81-76-265-2229 |
| Homepage URL | |
| bixiuqio@staff.kanazawa-u.ac.jp | |
| Sponsor | |
| Institute | Graduate school of Medicine, Kanazawa University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japan Society for the Promotion of Science |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | National Hospital of Pediatrics, Hanoi, Vietnam |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | This is a prospective study. HIV-infected children will be followed up and their immune situation will be analyzed before ART and 6,12,18,24 months after ART start. HIV-negative children will be analyzed only for one time as control. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000017218 |